Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 18/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630501 | 1.00 | RBP4 (1.00) | RBP4AKR1C3MEN1LMNAPOLB | |
| SCHEMBL767062 | 0.90 | RBP4 (0.81) | RBP4AKR1C3 | |
| SCHEMBL27873708 | 0.89 | RBP4 (0.80) | RBP4AKR1C3MEN1LMNAPOLB | |
| SCHEMBL766261 | 0.88 | RBP4 (0.79) | RBP4AKR1C3 | |
| SCHEMBL631783 | 0.88 | RBP4 (0.78) | RBP4AKR1C3MEN1LMNAPOLB | |
| SCHEMBL630839 | 0.86 | RBP4 (0.75) | RBP4AKR1C3 | |
| SCHEMBL766438 | 0.85 | RBP4 (0.73) | RBP4MEN1KMT2A | |
| SCHEMBL631908 | 0.85 | RBP4 (0.73) | RBP4MEN1KMT2A | |
| SCHEMBL766323 | 0.85 | RBP4 (0.87) | RBP4MEN1LMNAPOLBTSHR | |
| SCHEMBL631476 | 0.84 | RBP4 (0.73) | RBP4AKR1C3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | PDE6C, SERPINA6, PDE6H | RBP4 11/4885AKR1C3 1158/4885MEN1 2416/4885 |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | AGER, RBP4, RBP1 | RBP4 2/4885AKR1C3 1701/4885MEN1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.